The role of the PD-1 pathway in autoimmunity and peripheral tolerance

Annals of the New York Academy of Sciences

Volumn 1217, Issue 1, 2011, Pages 45-59

  Fife, Brian T ^a   Pauken, Kristen E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Autoimmune; Diabetes; PD 1; T cell; Tolerance

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR;

ARTICLE; AUTOIMMUNITY; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 79251571760     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05919.x     Document Type: Article

References (131)

1. van Noort, J.M., A. van Sechel, J. Boon, et al 1993. Minor myelin proteins can be major targets for peripheral blood T cells from both multiple sclerosis patients and healthy subjects. J. Neuroimmunol. 46: 67-72.
2. Lohmann, T., R.D. Leslie & M. Londei 1996. T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes. J. Autoimmun. 9: 385-389.
3. Salomon, B. & J.A. Bluestone 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19: 225-252.
4. Mueller, D.L. 2010. Mechanisms maintaining peripheral tolerance. Nat. Immunol. 11: 21-27.
5. Keir, M.E., M.J. Butte, G.J. Freeman & A.H. Sharpe 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704.
6. Fife, B.T. & J.A. Bluestone 2008. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224: 166-182.
7. Lafferty, K.J. & A.J. Cunningham 1975. A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. 53: 27-42.
8. Jenkins, M.K., D.M. Pardoll, J. Mizuguchi, et al 1987. Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc. Natl. Acad. Sci. USA 84: 5409-5413.
9. Schwartz, R.H., D.L. Mueller, M.K. Jenkins & H. Quill 1989. T-cell clonal anergy. Cold Spring Harb. Symp. Quant. Biol. 54(Pt 2): 605-610.
10. Walunas, T.L., D.J. Lenschow, C.Y. Bakker, et al 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413.
11. Linsley, P.S., P.M. Wallace, J. Johnson, et al 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257: 792-795.
12. -) thymocytes. Int. Immunol. 8: 773-780.
13. Chemnitz, J.M., R.V. Parry, K.E. Nichols, et al 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173: 945-954.
14. Agata, Y., A. Kawasaki, H. Nishimura, et al 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8: 765-772.
15. Vibhakar, R., G. Juan, F. Traganos, et al 1997. Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp. Cell Res. 232: 25-28.
16. Freeman, G.J., A.J. Long, Y. Iwai, et al 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
17. Sandner, S.E., M.R. Clarkson, A.D. Salama, et al 2005. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 174: 3408-3415.
18. Parry, R.V., J.M. Chemnitz, K.A. Frauwirth, et al 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 25: 9543-9553.
19. Dong, H., G. Zhu, K. Tamada & L. Chen 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5: 1365-1369.
20. Ishida, M., Y. Iwai, Y. Tanaka, et al 2002. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84: 57-62.
21. Latchman, Y., C.R. Wood, T. Chernova, et al 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2: 261-268.
22. Zhang, X., J.C. Schwartz, X. Guo, et al 2004. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20: 337-347.
23. Greenwald, R.J., G.J. Freeman & A.H. Sharpe 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548.
24. Nishimura, H., N. Minato, T. Nakano & T. Honjo 1998. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10: 1563-1572.
25. Nishimura, H., M. Nose, H. Hiai, et al 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.
26. Nishimura, H., T. Okazaki, Y. Tanaka, et al 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319-322.
27. Wang, J., T. Yoshida, F. Nakaki, et al 2005. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. USA 102: 11823-11828.
28. Tivol, E.A., F. Borriello, A.N. Schweitzer, et al 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
29. Waterhouse, P., J.M. Penninger, E. Timms, et al 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
30. Okazaki, T. & T. Honjo 2006. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27: 195-201.
31. Brown, J.A., D.M. Dorfman, F.R. Ma, et al 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170: 1257-1266.
32. Yamazaki, T., H. Akiba, H. Iwai, et al 2002. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169: 5538-5545.
33. Ansari, M.J., A.D. Salama, T. Chitnis, et al 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198: 63-69.
34. Loke, P. & J.P. Allison 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100: 5336-5341.
35. Liang, S.C., Y.E. Latchman, J.E. Buhlmann, et al 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33: 2706-2716.
36. Lee, I., L. Wang, A.D. Wells, et al 2003. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J. Immunol. 171: 6929-6935.
37. Kinter, A.L., E.J. Godbout, J.P. McNally, et al 2008. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181: 6738-6746.
38. Gong, A.Y., R. Zhou, G. Hu, et al 2009. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J. Immunol. 182: 1325-1333.
39. Keir, M.E., S.C. Liang, I. Guleria, et al 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203: 883-895.
40. Fife, B.T., I. Guleria, M. Gubbels Bupp, et al 2006. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203: 2737-2747.
41. Fife, B.T., K.E. Pauken, T.N. Eagar, et al 2009. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10(11): 1185-1192.
42. Luhder, F., P. Hoglund, J.P. Allison, et al 1998. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187: 427-432.
43. Miller, S.D., R.P. Wetzig & H.N. Claman 1979. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J. Exp. Med. 149: 758-773.
44. Salama, A.D., T. Chitnis, J. Imitola, et al 2003. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198: 71-78.
45. Zhu, B., I. Guleria, A. Khosroshahi, et al 2006. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J. Immunol. 176: 3480-3489.
46. Carter, L.L., M.W. Leach, M.L. Azoitei, et al 2007. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 182: 124-134.
47. Cheng, X., Z. Zhao, E. Ventura, et al 2007. The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. J. Neuroimmunol. 185: 75-86.
48. Wang, C., B. Dehghani, Y. Li, et al 2009. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 126: 329-335.
49. Kroner, A., N. Schwab, C.W. Ip, et al 2009. Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. Am. J. Pathol. 174: 2290-2299.
50. Schreiner, B., S.L. Bailey, T. Shin, et al 2008. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur. J. Immunol. 38: 2706-2717.
51. Elhofy, A., R.W. Depaolo, S.A. Lira, et al 2009. Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis. J. Neuroimmunol. 213: 91-99.
52. Wang, G., P. Hu, J. Yang, et al 2009. The effects of PDL-Ig on collagen-induced arthritis. Rheumatol. Int.
53. Raptopoulou, A.P., G. Bertsias, D. Makrygiannakis, et al 2010. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 62: 1870-1880.
54. Katz, J.D., B. Wang, K. Haskins, et al 1993. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74: 1089-1100.
55. Anderson, M.S. & J.A. Bluestone 2005. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23: 447-485.
56. Andre, I., A. Gonzalez, B. Wang, et al 1996. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl. Acad. Sci. USA 93: 2260-2263.
57. Guleria, I., M. Gubbels Bupp, S. Dada, et al 2007. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin. Immunol. 125: 16-25.
58. Guleria, I., A. Khosroshahi, M.J. Ansari, et al 2005. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 202: 231-237.
59. Petroff, M.G., L. Chen, T.A. Phillips, et al 2003. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol. Reprod. 68: 1496-1504.
60. Habicht, A., S. Dada, M. Jurewicz, et al 2007. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J. Immunol. 179: 5211-5219.
61. Aluvihare, V.R., M. Kallikourdis & A.G. Betz 2004. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5: 266-271.
62. Francisco, L.M., V.H. Salinas, K.E. Brown, et al 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206: 3015-3029.
63. Zhou, Q., M.E. Munger, S.L. Highfill, et al 2010. Program death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced acute myeloid leukemia (AML). Blood.
64. Worbs, T., U. Bode, S. Yan, et al 2006. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J. Exp. Med. 203: 519-527.
65. Zhang, Y., Y. Chung, C. Bishop, et al 2006. Regulation of T cell activation and tolerance by PDL2. Proc. Natl. Acad. Sci. USA 103: 11695-11700.
66. Matsumoto, K., H. Inoue, T. Nakano, et al 2004. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J. Immunol. 172: 2530-2541.
67. Oflazoglu, E., D.A. Swart, P. Anders-Bartholo, et al 2004. Paradoxical role of programmed death-1 ligand 2 in Th2 immune responses in vitro and in a mouse asthma model in vivo. Eur. J. Immunol. 34: 3326-3336.
68. Akbari, O., P. Stock, A.K. Singh, et al 2010. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal. Immunol. 3: 81-91.
69. Stoll, S., J. Delon, T.M. Brotz & R.N. Germain 2002. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296: 1873-1876.
70. Wei, S.H., M.J. Miller, M.D. Cahalan & I. Parker 2002. Two-photon imaging in intact lymphoid tissue. Adv. Exp. Med. Biol. 512: 203-208.
71. Bousso, P. & E.A. Robey 2004. Dynamic behavior of T cells and thymocytes in lymphoid organs as revealed by two-photon microscopy. Immunity 21: 349-355.
72. Hugues, S., L. Fetler, L. Bonifaz, et al 2004. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat. Immunol. 5: 1235-1242.
73. Mempel, T.R., S.E. Henrickson & U.H. Von Andrian 2004. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427: 154-159.
74. Miller, M.J., S.H. Wei, I. Parker & M.D. Cahalan 2002. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 296: 1869-1873.
75. Shakhar, G., R.L. Lindquist, D. Skokos, et al 2005. Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat. Immunol. 6: 707-714.
76. Tang, Q., J.Y. Adams, A.J. Tooley, et al 2006. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 7: 83-92.
77. Bajenoff, M., J.G. Egen, L.Y. Koo, et al 2006. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 25: 989-1001.
78. Catron, D.M., A.A. Itano, K.A. Pape, et al 2004. Visualizing the first 50 hr of the primary immune response to a soluble antigen. Immunity 21: 341-347.
79. Henrickson, S.E., T.R. Mempel, I.B. Mazo, et al 2008. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat. Immunol. 9: 282-291.
80. Henrickson, S.E., T.R. Mempel, I.B. Mazo, et al 2008. In vivo imaging of T cell priming. Sci. Signal. 1: pt2.
81. Negulescu, P.A., T.B. Krasieva, A. Khan, et al 1996. Polarity of T cell shape, motility, and sensitivity to antigen. Immunity 4: 421-430.
82. Dustin, M.L., S.K. Bromley, Z. Kan, et al 1997. Antigen receptor engagement delivers a stop signal to migrating T lymphocytes. Proc. Natl. Acad. Sci. USA 94: 3909-3913.
83. Fooksman, D.R., S. Vardhana, G. Vasiliver-Shamis, et al 2010. Functional anatomy of T cell activation and synapse formation. Annu. Rev. Immunol. 28: 79-105.
84. Hurez, V., A. Saparov, A. Tousson, et al 2003. Restricted clonal expression of IL-2 by naive T cells reflects differential dynamic interactions with dendritic cells. J. Exp. Med. 198: 123-132.
85. Benvenuti, F., C. Lagaudriere-Gesbert, I. Grandjean, et al 2004. Dendritic cell maturation controls adhesion, synapse formation, and the duration of the interactions with naive T lymphocytes. J. Immunol. 172: 292-301.
86. Gett, A.V., F. Sallusto, A. Lanzavecchia & J. Geginat 2003. T cell fitness determined by signal strength. Nat. Immunol. 4: 355-360.
87. van Stipdonk, M.J., E.E. Lemmens & S.P. Schoenberger 2001. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol. 2: 423-429.
88. Scholer, A., S. Hugues, A. Boissonnas, et al 2008. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity 28: 258-270.
89. Celli, S., F. Lemaitre & P. Bousso 2007. Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation. Immunity 27: 625-634.
90. Skokos, D., G. Shakhar, R. Varma, et al 2007. Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes. Nat. Immunol. 8: 835-844.
91. Garcia, Z., E. Pradelli, S. Celli, et al 2007. Competition for antigen determines the stability of T cell-dendritic cell interactions during clonal expansion. Proc. Natl. Acad. Sci. USA 104: 4553-4558.
92. Schneider, H., J. Downey, A. Smith, et al 2006. Reversal of the TCR stop signal by CTLA-4. Science 313: 1972-1975.
93. Downey, J., A. Smith, H. Schneider, et al 2008. TCR/CD3 mediated stop-signal is decoupled in T-cells from Ctla4 deficient mice. Immunol. Lett. 115: 70-72.
94. Eagar, T.N., D.M. Turley, J. Padilla, et al 2004. CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. J. Immunol. 172: 7442-7450.
95. Okazaki, T. & T. Honjo 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824.
96. Prokunina, L., C. Castillejo-Lopez, F. Oberg, et al 2002. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32: 666-669.
97. Ferreiros-Vidal, I., J.J. Gomez-Reino, F. Barros, et al 2004. Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. Arthritis Rheum. 50: 2590-2597.
98. Wang, S.C., Y.J. Chen, T.T. Ou, et al 2006. Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J. Clin. Immunol. 26: 506-511.
99. Nielsen, C., D. Hansen, S. Husby, et al 2003. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62: 492-497.
100. Ni, R., K. Ihara, K. Miyako, et al 2007. PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. Hum. Genet. 121: 223-232.
101. Kroner, A., M. Mehling, B. Hemmer, et al 2005. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann. Neurol. 58: 50-57.
102. Lin, S.C., J.H. Yen, J.J. Tsai, et al 2004. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum. 50: 770-775.
103. Prokunina, L., L. Padyukov, A. Bennet, et al 2004. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum. 50: 1770-1773.
104. Kong, E.K., L. Prokunina-Olsson, W.H. Wong, et al 2005. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum. 52: 1058-1062.
105. Helms, C., L. Cao, J.G. Krueger, et al 2003. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. 35: 349-356.
106. Lee, S.H., Y.A. Lee, D.H. Woo, et al 2006. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res. Ther. 8: R163.
107. Kobayashi, M., S. Kawano, S. Hatachi, et al 2005. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome. J. Rheumatol. 32: 2156-2163.
108. Bolstad, A.I., H.G. Eiken, B. Rosenlund, et al 2003. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum. 48: 174-185.
109. Hatachi, S., Y. Iwai, S. Kawano, et al 2003. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol. 30: 1410-1419.
110. Wan, B., H. Nie, A. Liu, et al 2006. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177: 8844-8850.
111. Reynoso, E.D., K.G. Elpek, L. Francisco, et al 2009. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J. Immunol. 182: 2102-2112.
112. Wang, C.J., F.C. Chou, C.H. Chu, et al 2008. Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models. Diabetes 57: 1861-1869.
113. Subudhi, S.K., P. Zhou, L.M. Yerian, et al 2004. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J. Clin. Invest. 113: 694-700.
114. Butte, M.J., M.E. Keir, T.B. Phamduy, et al 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
115. Park, J.J., R. Omiya, Y. Matsumura, et al 2010. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T cell tolerance. Blood 116: 1291-1298.
116. Yantha, J., H. Tsui, S. Winer, et al 2010. Unexpected Acceleration of Type 1 Diabetes by Transgenic Expression of B7-H1 in NOD Mouse Peri Islet Glia. Diabetes 59: 2588-2596.
117. Iwai, Y., M. Ishida, Y. Tanaka, et al 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99: 12293-12297.
118. Blank, C., I. Brown, A.C. Peterson, et al 2004. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64: 1140-1145.
119. Dong, H., S.E. Strome, D.R. Salomao, et al 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
120. Day, C.L., D.E. Kaufmann, P. Kiepiela, et al 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
121. Urbani, S., B. Amadei, D. Tola, et al 2008. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. J. Hepatol. 48: 548-558.
122. Boettler, T., E. Panther, B. Bengsch, et al 2006. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virol. 80: 3532-3540.
123. Dong, H. & X. Chen 2006. Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol. Immunol. 3: 179-187.
124. Barber, D.L., E.J. Wherry, D. Masopust, et al 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
125. Martinic, M.M. & M.G. von Herrath 2008. Novel strategies to eliminate persistent viral infections. Trends Immunol. 29: 116-124.
126. Bennett, F., D. Luxenberg, V. Ling, et al 2003. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J. Immunol. 170: 711-718.
127. Hirata, S., S. Senju, H. Matsuyoshi, et al 2005. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J. Immunol. 174: 1888-1897.
128. Griffin, M.D., P.O. Holman, Q. Tang, et al 2001. Development and applications of surface-linked single chain antibodies against T-cell antigens. J. Immunol. Methods 248: 77-90.
129. Fife, B.T., M.D. Griffin, A.K. Abbas, et al 2006. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Invest. 116: 2252-2261.
130. Hwang, K.W., W.B. Sweatt, I.E. Brown, et al 2002. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J. Immunol. 169: 633-637.
131. Ding, H., X. Wu, J. Wu, et al 2006. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin. Immunol. 118: 258-267.